# The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

> **NCT05913817** · — · COMPLETED · sponsor: **Jamp Pharma Corporation** · enrollment: 324 (actual)

## Conditions studied

- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
- Hidradenitis Suppurativa

## Interventions

- **BIOLOGICAL:** AVT02 (Alvotech Biosimilar to Adalimumab)

## Key facts

- **NCT ID:** NCT05913817
- **Lead sponsor:** Jamp Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-08-25
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913817, "The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05913817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*